Sunday Week Ahead
May 18-24, 2026
Market | The Setup
The S&P 500 closed Friday at fresh all-time highs. The Nasdaq joined it. The Dow continues teasing 50,000 but lagged slightly. The tape is firm and the momentum is real — the question now is whether it holds once the macro data this week gives the market something to react to.
Three prints matter. Tuesday brings Pending Home Sales for April. Wednesday is the FOMC Minutes from the May meeting. Thursday delivers the full housing and labor package — Initial Jobless Claims, Housing Starts, Building Permits, and the Philly Fed Manufacturing Survey. No fresh CPI, PPI, or retail sales this week, which keeps the volatility ceiling lower than it could be. But if claims tick up or the minutes carry hawkish language on the pace of cuts, you’ll feel it in the small-cap tape immediately.
That’s exactly where our book lives, and that’s exactly the kind of dislocation we use. Mispriced small- and mid-cap names don’t need a perfect macro environment — they need a moment of noise to create an entry. Watch the claims print Thursday morning.
The bigger story running underneath all of it is the biotech M&A grind. Deals are getting done at a steady pace, mostly away from the headlines. Community banking is producing takeouts at the micro level and biotech is right alongside it. The sub-tape is more interesting than the indices right now. That’s our environment and we’re built for it.
M&A Watch | Two Names This Week
One is the near-term catalyst setup. One is the long-tail acquisition target. Different timelines, both worth building a position in.
MDAI — Spectral AI ~$2.37 | ~$75M Market Cap | Near-Term Catalyst
Dallas-based Spectral AI has built DeepView — an AI-powered wound assessment platform designed to deliver faster, more accurate treatment decisions in burn and diabetic ulcer care. The core value proposition is speed and objectivity at the point of care: DeepView uses multispectral imaging and machine learning to predict wound healing trajectory and optimal treatment path at a stage when clinical assessment alone is unreliable.
The FDA catalyst is the event. A De Novo 510(k) application was submitted in June 2025 for the DeepView System in the burn indication, with an FDA response expected by end of Q2 2026. That window is now. A clearance decision lands the company a commercial path in late 2026 and immediately reprices the asset for any acquirer already watching.
The balance sheet has been materially de-risked. In March 2026, MDAI announced $31.7 million in non-dilutive BARDA funding under an accelerated Phase II Project BioShield contract — the kind of government validation that removes a meaningful chunk of binary risk from the equation. Q1 2026 earnings reported May 12 showed continued progress on that contract and reiterated full-year revenue guidance of approximately $18.5 million. A new CFO is in place and the commercialization strategy was finalized with Deloitte. The company presented DeepView at the American Burn Association Annual Meeting in April.
The M&A logic is straightforward: AI diagnostics assets in wound care and med-tech are running at premium multiples for tuck-in deals right now. Sub-$100 million market cap, non-dilutive government funding, a pending FDA decision, and a tiny float is a textbook setup. Entry zone is the current $2.30–$2.40 range for builders. The 52-week floor sits around $2.00 and represents the support level worth watching if the FDA decision slips.
M&A Score 79 | Growth Score 82
MGNX — MacroGenics ~$4.35 | ~$43.5M Market Cap | Long-Tail M&A Target
MacroGenics sits near its lows with a market cap that barely registers for most institutional screens — which is precisely why it belongs on this list. The company has built a bispecific antibody platform with multiple shots on goal across oncology, and the combination of a clean capital structure, a deeply discounted valuation, and genuine pipeline optionality makes it exactly the kind of asset a large pharma acquirer picks up quietly before anyone else notices.
This is not an imminent catalyst play. This is a name you build slowly while the broader M&A environment continues to pressure Big Pharma toward all-cash deals in the sub-$6 billion range. MacroGenics fits that profile. Any positive read-through from the oncology conference cycle — particularly if a bispecific-adjacent name in the same mechanistic space gets data or a deal — could move this one faster than the timeline suggests. A fresh 13D filing would accelerate the thesis considerably.
Entry zone is current levels for patient builders. The downside is largely priced in at this valuation. The upside is the deal.
M&A Score 76 | Growth Score 62
Week Ahead | Dates and Watches
Monday May 18 ASGCT 2026 and PEGS Boston wrap final sessions — read-throughs from last week’s presentations are still flowing. WVE late-breaking oral at ATS at 4:03 PM ET, followed by investor call at 5:30 PM ET. New WVE-006 AATD data from two previously undisclosed cohorts. This is the most immediate catalyst in the book right now.
Tuesday May 19 Pending Home Sales, April — 10:00 AM ET.
Wednesday May 20 FOMC Minutes from May meeting — 2:00 PM ET. Watch for any language shift on the pace of cuts. Hawkish tone creates noise in small-cap biotech that we use.
Thursday May 21 Initial Jobless Claims, Housing Starts, Building Permits, Philly Fed — 8:30 AM ET. ASCO abstracts go live at 5:00 PM ET. This is the first public look at the full data texts for SMMT, IDYA, COGT, KURA, and every other oncology name presenting at Chicago. Expect movement across the book Thursday evening.
Ongoing MDAI — the FDA Q2 window for the DeepView burn decision is open. Any agency communication moves this one fast on a thin float. Keep alerts set.
RLAY — zovegalisib data momentum continues to create read-through pressure on PI3K-adjacent names in the book including ORIC and TYRA. Watch the tape on those two when RLAY moves.
13D filings — any new activity in small and mid-cap oncology, radiopharm, or AI diagnostics this week should be treated as signal. The deal pace underneath the tape is not slowing down.
ASCO Chicago opens May 29. Names with confirmed presentations are already being positioned. The abstract drop Thursday is when that positioning accelerates.
Education Corner | The 2030 Cliff Is the Real Story
A lot of commentary right now focuses on the 2026 patent cliff as though that’s the main event driving M&A activity. It isn’t. 2026 is the warm-up. The expirations happening this year are real but manageable for most of the large players involved. What is not manageable — and what is actually driving the acquisition pace we’re watching right now — is what hits between 2028 and 2032.
The 2030 window represents the largest patent expiry wave in the history of the pharmaceutical industry. Estimates put the revenue at risk somewhere between $200 and $400 billion annually across the major players by the time the full cliff arrives. Five of the top ten pharma companies are projected to lose between 30 and 50 percent of their current revenue base in that window. Keytruda, Opdivo, Eliquis, Stelara, and Eylea are all rolling off. These are not peripheral products. These are the assets that currently fund everything else.
Big Pharma cannot invent its way out of a hole that size on its internal timelines. Drug discovery and development from target identification to approval runs ten to fifteen years under optimal conditions. The math does not work. The only path is acquisition, and they know it.
This is why the deal environment in 2026 feels different from prior cycles. The companies writing checks right now are not acquiring for 2027 earnings. They are acquiring for 2030 survival. That urgency changes the premium calculus. It changes how aggressively they bid. It changes how quickly they move when an asset fits.
Our book is built exactly for this. Clinical-stage and early-commercial names with tight floats, real data, and differentiated mechanisms in oncology, rare disease, and gene therapy — sitting at market caps that a large pharma company can absorb in an all-cash deal without moving their own stock. That is the wheelhouse. That is where 2x to 5x outcomes come from in environments like this one.
The traders chasing the 2026 headlines will make some money. The hunters who understand what Big Pharma actually needs by 2030 will make multiples of that. Stay focused on the setup. The patent math does the heavy lifting.
Solid setup piece. The tape is firm and the macro week is loaded.
I read these to know what the market is reacting to, not what to buy. My job Monday morning is the same whether SPX prints a new high or rolls over on the FOMC minutes. $500 goes to the highest-conviction name on my list.